What Analysts Are Saying About Apple After the iPhone 7 Debut
Practically everyone had an opinion on the new iPhone 7, as well as where Apple and the iPhone family stand to go from here.
Practically everyone had an opinion on the new iPhone 7, as well as where Apple and the iPhone family stand to go from here.
Kroger is scheduled to release its fiscal second-quarter earnings report before the markets open on Friday.
Honeywell International took another step in its evolution when it announced that its board of directors has declared a pro rata dividend of AdvanSix common stock.
Pier 1 Imports gave a business update after the markets closed on Wednesday, revising its preliminary results and guidance and announcing a transition in management.
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in October. These catalyst events can make or break these companies.
Hewlett Packard Enterprise Co. (NYSE: HPE) reported its fiscal third-quarter financial results after markets closed on Wednesday. However these earnings were overshadowed by the company’s most recent spin-off and merger. The company said that…
Celgene is making a move out of left field that has sent shares of its partner Agios Pharmaceuticals significantly higher.
Evoke Pharma shares saw a handy gain on Wednesday following news of a positive meeting with the FDA over Gimoti.
Hewlett Packard Enterprise is scheduled to report its fiscal third-quarter financial results after the markets close on Wednesday.
Western Digital has been on the slide for the past couple of years, but Wednesday morning offered a shot of life for the company.
Shares of Retrophin climbed early on Wednesday following positive top-line news from its mid-stage trial for the treatment of focal segmental glomerulosclerosis.
24/7 Wall St. has put together a preview of Hewlett Packard Enterprise and some of the other notable companies reporting in the coming week.
What most investors are looking for is a solid solution in what is a confusing market. So we have compiled a list of a few biotech companies that fit the bill, and analysts are…
When Broadcom reported its most recent quarterly results on Thursday, revenues and earnings beat expectations, but this was not enough for investors.
Salesforce.com's share price drooped. This was not necessarily based on the latest quarterly numbers, but really it was the near-term guidance that failed to impress.
Even though the market has made incredible gains, a few companies held it back from pushing even higher, including SolarCity and Tesla Motors.
Smith & Wesson beat on the top and bottom lines, practically doubling its earnings year over year, but this was not enough for investors.
After Lululemon Athletica reported inline fiscal second-quarter earnings results, Merrill Lynch analysts were not impressed.
Ambarella reported its fiscal second-quarter financial results after the markets closed on Thursday and shares fell sharply Friday morning.
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in September.